当前位置: 首页 > 期刊 > 《中国当代医药》 > 2017年第21期
编号:13088055
高血压与焦虑抑郁共病的研究现状(4)
http://www.100md.com 2017年10月8日 《中国当代医药》 2017年第21期
     [21]Hafner S,Baumert J,Emeny RT,et al.Hypertension and depressed symptomatology: a cluster related to the activation of the rennin-angiotensin-aldosterone system(RAAS).Findings from population based KORA F4 study[J].Psychoneuroendocrinology,2013,38(10):2065-2074.

    [22]Nayak V,Patil PA.Antidepressant activity of fosinopril,ramipril and Iosartan,but not of lisinopril in depressive paradigms of albino rats and mice[J].Indian J Exp Biol,2008,46(3):180-184.

    [23]Nasr SJ,Crayton JW,Agarwal B,et al.Lower frequency of antidepressant use in patients on rennin-angiotensin-aldosterone system modifying medications[J].Cell Mol Neurobiol,2011,31(4):615-618.

    [24]曾国庆,刘忠镗,高晶,等.综合干预对高血压合并焦虑抑郁患者血压的影响[J].中华高血压杂志,2015,23(9):880-882.

    [25]王福军,向红菊,石翔,等.氟西汀对高血压伴焦虑抑郁患者治療效果和生活质量的影响[J].中华高血压杂志,2012,20(8):91-93.

    [26]Ohira T.Psychological distress and cardiovascular disease: the Criculatory Risk in Communities Study (CIRCS)[J].J Epidemiol,2010,20(3):185-191.

    [27]Tikhonoff V,Hardy R,Deanfiele J,et al.NSHD scientific and data collection teams[J].J Hypertens,2014,32(8):1590-1598.

    (收稿日期:2017-06-12 本文编辑:崔建中), 百拇医药(季润青 王友信)
上一页1 2 3 4